Patients with access to GeneSight results for depression treatment showed faster initial remission and response. The post-hoc analysis also found persistent benefit over six months, without evidence of changing over time.
A new study at SABCS finds EndoPredict, a second-generation test, superior to Oncotype Dx in predicting breast cancer recurrence. The test accurately identified patients with low risk of recurrence, allowing them to forgo chemotherapy.
Recent studies present new data on the myRisk Hereditary Cancer test, highlighting its ability to identify patients with deleterious mutations who may have been missed by traditional genetic testing. The test demonstrated a significant increase in identifying BRCA-related mutations among those tested without BRCA1/2 results.
The myChoice HRD test predicts response to DNA-damaging agents in ovarian, breast, and pancreatic cancers. A score of ?42 indicates a loss of DNA repair function and reflects tumor sensitivity to PARP inhibitors and platinum-based therapies.
The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Recent studies have found that the test identifies 100.8% more mutations than BRCA1/2 testing alone, including increased mutations in breast and ovarian cancer patients.
The Prolaris test helps physicians determine the aggressiveness of prostate cancer, enabling personalized treatment plans. In a clinical validation study, the test showed that at the active surveillance threshold, predicted 10-year survival rates were 97% and risk of mortality was 3%.
Myriad Genetics presented 19 clinical studies on advanced companion diagnostic and molecular diagnostic tests for cancer treatment and prevention. The company's research focuses on personalized medicine, including selecting effective pharmaceuticals, preventing disease through hereditary cancer tests, and optimizing treatment decisions...
Myriad Genetics to present three studies supporting the use of Prolaris in predicting outcomes and personalizing treatment plans for men with localized prostate cancer. The tests demonstrate a new active surveillance threshold and validate an active surveillance threshold, showing potential for improved care.
Myriad Genetics announced new studies on its myRisk Hereditary Cancer test, detecting 105% more mutations than conventional BRCA testing. The test also showed promising results in triple negative breast cancer (TNBC) by predicting response to platinum-based therapy. Additionally, the company's BRACAnalysis molecular diagnostic test sig...
The Prolaris test could save the healthcare system $6 billion over 10 years by reducing costs and improving health outcomes. The test improves health outcomes, reduces healthcare costs, and aids physicians in providing clinical care for their patients.
New clinical data show Vectra DA is a strong predictor of radiographic progression over two years compared to other tests used to assess risk of joint damage. The study found that among patients with low CRP, high Vectra DA scores were associated with increased risk of radiographic progression.
Crescendo Bioscience will showcase new clinical data on Vectra DA at the 2014 ACR Annual Meeting, highlighting its value in assessing RA disease activity and predicting patient risk of joint damage. The company will present two oral presentations and four poster presentations.
The Myriad myPath Melanoma test has been shown to improve patient care through more definitive diagnoses of skin lesions, particularly in difficult-to-call cases. This resulted in a 49% change in physicians' treatment recommendations for patients with melanoma subtypes.
A study by Myriad Genetics presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting shows that its Tumor BRACAnalysis CDx test identifies cancer-causing BRCA1/2 mutations in 44% more patients than germline blood testing. This could expand treatment options for ovarian cancer patients with these genetic mutations.
The myPath Melanoma test differentiates malignant melanoma from benign skin lesions with over 90% accuracy, reducing indeterminate diagnoses by 76%. This improved diagnostic tool also changed treatment recommendations in 35% of cases, supporting its integration into clinical practice.
Vectra DA data demonstrates clinical utility in assessing risk of future joint damage, with high scores associated with radiographic progression. The test may help identify patients at higher or lower risks for radiographic progression while receiving antirheumatic therapy.
The Myriad myPath Melanoma test accurately differentiates malignant melanoma from benign skin lesions with a sensitivity of 90% and specificity of 91%. This improves the standard of care for patients with melanoma, enabling healthcare providers to deliver more objective and confident diagnoses.
The Myriad myRisk test detects significantly more deleterious mutations than single cancer tests and helps solve the overlap dilemma among hereditary cancer syndromes. The test evaluates 25 clinically significant genes associated with eight major hereditary cancers.
Myriad Genetics Inc. presented new data on its BRACAnalysis CDx and HRD tests, supporting their clinical efficacy in predicting platinum-based therapy response for triple negative breast cancer patients. The company also announced an early access launch of the HRD test in FY15.
The Prolaris test accurately predicted 10-year death rates from prostate cancer and outperformed antiquated upgrading practice. In conservatively managed patients, the test differentiated high-risk disease from lower-risk disease.
The Milieu Interieur Project characterizes healthy human immune responses using TruCulture technology, a proprietary blood collection system. The study reveals unique patterns of immune responses to complex stimuli, shedding light on genetic and environmental causes of immune variations.
The PROCEDE 500 study demonstrates that the Prolaris test provides personalized risk assessment for prostate cancer patients, leading to significant changes in treatment plans. The study found a 50% reduction in surgical interventions and a 30% reduction in radiation treatment.
The PROCEDE 500 clinical utility study demonstrates the significant clinical value of Prolaris to physicians treating men with prostate cancer. The test accurately predicts prostate cancer-specific death and metastases, guiding treatment decisions and reducing therapeutic burden on patients.